June 08, 2011 06:00 ET

InVivo Therapeutics Announces Major Patent Expansion to Include Additional Nervous System Conditions


CAMBRIDGE, MA--(Marketwire - Jun 8, 2011) -InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced it has expanded the "Field of Use" of its existing patent license to include parts of the peripheral nervous system, the cavernous nerve surrounding the prostate, the brain, the retina and cranial nerves. InVivo has an exclusive, worldwide license to a broad suite of patents, co-owned by the Massachusetts Institute of Technology and Harvard's Children's Hospital (the "CMCC License").